• 1. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 2. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Introduction to 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine (CAS No. 1370001-96-9)

4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its CAS number 1370001-96-9, is a key intermediate in the synthesis of various biologically active molecules. Its unique structural features, particularly the presence of a pyrimidine core and a tetramethyl-1,3,2-dioxaborolan-2-yl substituent, make it a valuable building block for the development of novel therapeutic agents.

The pyrimidine scaffold is a fundamental motif in many natural and synthetic bioactive compounds. Pyrimidines are essential components of nucleic acids (DNA and RNA) and serve as precursors to numerous pharmacologically relevant molecules. The incorporation of a methyl group at the 4-position and a boronate ester functionality at the 5-position further enhances the compound's utility in synthetic chemistry. This modification allows for facile functionalization via cross-coupling reactions, making it an attractive candidate for constructing complex molecular architectures.

The tetramethyl-1,3,2-dioxaborolan-2-yl group is another critical feature of this compound. Boronate esters are well-known for their ability to participate in palladium-catalyzed cross-coupling reactions, such as the Suzuki-Miyaura coupling. These reactions are cornerstone techniques in modern organic synthesis and have been widely employed in the construction of carbon-carbon bonds in drug candidates. The stability and reactivity of the boronate ester moiety make it an ideal choice for introducing aryl or heteroaryl groups into a molecular framework.

In recent years, there has been growing interest in developing new methodologies for the synthesis of pyrimidine derivatives with potential therapeutic applications. The compound 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine has been explored in several innovative research projects aimed at discovering novel pharmacophores. For instance, studies have demonstrated its utility in generating substituted pyrimidines that exhibit inhibitory activity against various enzymes and receptors implicated in human diseases.

One notable area of research involves the use of this compound in the development of antiviral agents. Pyrimidine derivatives have shown promise as inhibitors of viral polymerases and integrases. The structural versatility offered by 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine allows chemists to fine-tune the properties of these derivatives to optimize their binding affinity and selectivity. Recent publications highlight its role in synthesizing potent inhibitors of RNA-dependent RNA polymerases (RdRp), which are crucial for viral replication cycles.

Another emerging application of this compound is in the field of anticancer drug discovery. Pyrimidine-based molecules have long been recognized for their ability to interfere with key cellular processes such as DNA replication and transcription. Researchers have leveraged the synthetic potential of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine to develop small molecule inhibitors targeting kinases and other enzymes involved in cancer progression. Preliminary studies indicate that certain derivatives exhibit significant cytotoxicity against multiple cancer cell lines while maintaining acceptable levels of selectivity toward normal cells.

The chemical synthesis of 4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine is another area where this compound has made notable contributions. Advances in boron chemistry have enabled more efficient and scalable routes to boronate esters without compromising purity or yield. These improvements have not only streamlined the production process but also opened doors for exploring novel synthetic strategies that were previously inaccessible due to technical limitations.

The versatility of this compound extends beyond its role as a synthetic intermediate. Its unique reactivity profile has been exploited in various cross-coupling reactions that are fundamental to modern drug discovery pipelines. For example,Suzuki-Miyaura couplings involving this boronate ester have been used to construct biaryl systems with potential applications as kinase inhibitors or modulators of other signaling pathways implicated in diseases such as diabetes and neurodegeneration.

In conclusion,4-methyl-5-(4,4,5，tetratmethyl-l，3，2-dioxaborolane-zyl)Pyrimidine (CAS No. 1370001—96—9) represents a significant advancement in pharmaceutical chemistry。 Its combination o f structural features makes it an invaluable tool f or designing novel therapeutic agents。 The ongoing research into its applications i n antiviral、 anticancer、and other therapeutic areas underscores its importance i n advancing drug discovery efforts worldwide。

• 321724-19-0(5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 2369772-10-9(2-Methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 2417014-06-1(5-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-4-(trifluoromethyl)pyrimidine)
• 1817776-39-8(4-Cyclopropyl-6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 1375303-49-3(4-Cyclopropyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 944401-55-2(4-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-YL)pyrimidin-2-amine)
• 1951411-55-4(2-Isopropoxy-4-methyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrimidine)
• 1430233-43-4(4,6-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)Pyrimidine)
• 2223052-31-9(2-chloro-4-methyl-5-(tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)
• 1951411-46-3(2,4-Dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine)